Aldose reductase inhibitors are a class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (blood sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. A medication is a licenced drug taken to cure or reduce symptoms of an illness or medical condition. ... This article needs to be cleaned up to conform to a higher standard of quality. ... Nerves redirects here. ... This article is about the disease that features high blood sugar. ... wuzz up peeps, hows it hangin? lol, lv ya all! Its alrite thx lol! fuk dis is a borin lesn! lv ya all! every1 reply! i know lol, hows cris? hes alrite, big dick! lol! hi peeps how r u all im alrite thx hun! u? fine who were you... Glucose (Glc), a simple monosaccharide sugar, is one of the most important carbohydrates and is used as a source of energy in animals and plants. ... Sorbitol, also known as glucitol, is a sugar alcohol the body metabolises slowly. ... Retinopathy is a general term that refers to some form of non-inflammatory damage to the retina of the eye. ... Neuropathy is a disease of the peripheral nervous system. ...
Surrogate measure of such drugs-effect is decreasing of sorbitol level in blood-erythrocytes. NIH can refer to: National Institutes of Health Norwegian School of Sports Sciences: (Norges idrettshøgskole - NIH) Not Invented Here This is a disambiguation page â a navigational aid which lists other pages that might otherwise share the same title. ...
In animal studies, giving a compound from the family of aldosereductaseinhibitors stopped the deadly inflammation of sepsis, which is caused by the overreaction of the immune system to a bacterial infection, according to a report in the Oct. 9 online issue of.
One aldosereductaseinhibitor, fiderestat, has been approved for use in Japan, and an application for its use in the United States is expected soon.
One reason for hope is that the aldosereductaseinhibitors appear to stop production of all the toxins causing physical damage, Wiedemann said, but he still counseled caution based on previous experience.